Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

Barbara E. Drevlow, Rosa Lovis, Mary Ann Haag, James M. Sinacore, Cindy Jacobs, Consuelo Blosche, Alan Landay, Larry W. Moreland, Richard M. Pope*

*Corresponding author for this work

Research output: Contribution to journalArticle

79 Scopus citations

Abstract

Objective. To determine the safety and efficacy of recombinant soluble human interleukin-1 receptor type I (rHuIL-1RI) administered subcutaneously in patients with active rheumatoid arthritis (RA). Methods. Twenty-three patients with active RA (>5 swollen joints) were enrolled into a randomized, double-blind, 2-center study. Patients received subcutaneous doses of rHuIL- IRI or placebo for 28 consecutive days. Patients were treated with 125, 250, 500, or 1,000 μg/m2/day of rHuIL-1RI. Physical examinations and laboratory assessments were performed at baseline (day 1), and 8, 15, 22, 29, 43, and 57 days after the start of the study. Analysis of peripheral blood by flow cytometry was performed on days 1 and 29 to determine the effects of rHuIL- 1RI on the distribution and phenotypic characteristics of circulating inflammatory cells. Results. Four of 8 patients who received rHuIL-1RI at 1,000 μg/m2/day demonstrated improvement in at least I of 8 individual measures of disease activity; however, only 1 of these 4 patients experienced clinically relevant improvement as defined by predetermined criteria. None of the patients treated with smaller doses of rHuIL-1RI, and none of the placebo-treated control patients, experienced any improvement as defined by the predetermined criteria. Monocyte cell surface IL-1α was significantly reduced following treatment with rHulL-1RI at each dosage. Administration of rHuIL-1RI was stopped prematurely because of dose-limiting rashes in 2 patients treated with 1,000 μg/m2/day. No other adverse events prevented completion of the study. Conclusion. Only 1 patient, who was treated with the highest concentration of rHuIL-1RI employed (1,000 μg/m2/day), demonstrated clinically relevant improvement in this phase I study on this small group of patients with active RA. Dose-limiting toxicity was also observed in 2 patients treated with this highest concentration of rHuIL-1RI. Treatment with rHuIL-1RI did result in a reduction of monocyte cell surface IL-1α, which indicates that the dosages of rHuIL-1RI employed were functional.

Original languageEnglish (US)
Pages (from-to)257-265
Number of pages9
JournalArthritis and rheumatism
Volume39
Issue number2
DOIs
StatePublished - Feb 1996

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis'. Together they form a unique fingerprint.

  • Cite this

    Drevlow, B. E., Lovis, R., Haag, M. A., Sinacore, J. M., Jacobs, C., Blosche, C., Landay, A., Moreland, L. W., & Pope, R. M. (1996). Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis and rheumatism, 39(2), 257-265. https://doi.org/10.1002/art.1780390212